


**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

Claim 1. (Currently amended) A compound of formula I



wherein

X is O, ~~NH~~, ~~N(C<sub>1-4</sub>)alkyl~~, ~~CO~~ or ~~CHOH~~,

Y is CH or ~~N~~,

A and B are each hydrogen or together form a second bond between the carbon atoms to which they are attached,

R<sub>1</sub> is hydrogen or ~~(C<sub>1-4</sub>)alkyl~~ (C<sub>1-4</sub>)alkyl,

R<sub>2</sub> is optionally substituted (C<sub>1-8</sub>)alkyl, (C<sub>3-7</sub>)cycloalkyl, (C<sub>3-7</sub>)cycloalkyl(C<sub>1-4</sub>)alkyl, aryl or heteroaryl,

R<sub>3</sub> is CH(R<sub>e</sub>)CONR<sub>a</sub>R<sub>b</sub> or (CH<sub>2</sub>)<sub>n</sub>NR<sub>c</sub>R<sub>d</sub>,

n is 0, 1 or 2,

R<sub>a</sub>, R<sub>b</sub>, R<sub>c</sub> and R<sub>d</sub>, independently, are hydrogen or optionally substituted (C<sub>1-8</sub>)alkyl, (C<sub>3-7</sub>)cycloalkyl, (C<sub>3-7</sub>)cycloalkyl(C<sub>1-4</sub>)alkyl, (C<sub>7-9</sub>)bicycloalkyl, 1-aza-(C<sub>7-9</sub>)bicycloalkyl, aryl, aryl(C<sub>1-4</sub>)alkyl, heteroaryl, heteroaryl(C<sub>1-4</sub>)alkyl or heterocyclyl, or

R<sub>a</sub>, R<sub>b</sub>, R<sub>c</sub> and R<sub>d</sub>, together with the nitrogen to which they are attached, form an optionally substituted pyrrolidiny, piperidino, morpholino or piperazinyl group,

R<sub>e</sub> is (C<sub>1-8</sub>)alkyl, (C<sub>1-4</sub>)alkoxy(C<sub>1-4</sub>)alkyl, (C<sub>3-7</sub>)cycloalkyl or (C<sub>3-7</sub>)cycloalkyl(C<sub>1-4</sub>)alkyl, and

R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub> and R<sub>9</sub>, independently, are hydrogen, (C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkoxy, (C<sub>1-4</sub>)alkyl-SO<sub>2</sub>, cyano, nitro or halogen, in free base or acid addition salt form.

Claim 2. (Currently amended) A compound of formula I according to claim 1 wherein

X is O, ~~NH~~, ~~N(C<sub>1-4</sub>)alkyl~~, ~~CO~~ or ~~CHOH~~,

Y is CH or ~~N~~,

A and B are each hydrogen or together form a second bond between the carbon atoms to which they are attached,

R<sub>1</sub> is hydrogen or (C<sub>1-4</sub>)alkyl,

R<sub>2</sub> is optionally substituted (C<sub>1-8</sub>)alkyl, (C<sub>3-7</sub>)cycloalkyl, (C<sub>3-7</sub>)cycloalkyl(C<sub>1-4</sub>)alkyl, aryl or heteroaryl,

R<sub>3</sub> is CH(R<sub>e</sub>)CONR<sub>a</sub>R<sub>b</sub> or (CH<sub>2</sub>)<sub>n</sub>NR<sub>c</sub>R<sub>d</sub>,

n is 0, 1 or 2,

R<sub>a</sub>, R<sub>b</sub>, R<sub>c</sub> and R<sub>d</sub>, independently, are hydrogen or optionally substituted (C<sub>1-8</sub>)alkyl, (C<sub>3-7</sub>)cycloalkyl, (C<sub>3-7</sub>)cycloalkyl(C<sub>1-4</sub>)alkyl, aryl, aryl(C<sub>1-4</sub>)alkyl, heteroaryl or heteroaryl(C<sub>1-4</sub>)alkyl or

R<sub>a</sub>, R<sub>b</sub>, R<sub>c</sub> and R<sub>d</sub>, together with the nitrogen to which they are attached, form an optionally substituted pyrrolidinyl, piperidino, morpholino or piperazinyl group,

R<sub>e</sub> is (C<sub>1-8</sub>)alkyl, (C<sub>1-4</sub>)alkoxy(C<sub>1-4</sub>)alkyl, (C<sub>3-7</sub>)cycloalkyl or (C<sub>3-7</sub>)cycloalkyl(C<sub>1-4</sub>)alkyl, and

R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub> and R<sub>9</sub>, independently, are hydrogen, (C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkoxy, (C<sub>1-4</sub>)alkyl-SO<sub>2</sub>, cyano, nitro or halogen, in free base or acid addition salt form.

Claim 3. (Currently amended) A compound of formula I according to claim 1 wherein

X is O, ~~NH~~ or ~~CO~~,

Y is CH or ~~N~~,

A and B are each hydrogen or together form a second bond between the carbon atoms to which they are attached,

R<sub>1</sub> is hydrogen,

R<sub>2</sub> is (C<sub>1-4</sub>)alkyl, or phenyl, which is unsubstituted or substituted by hydroxy, amino or halogen,

R<sub>3</sub> is CH(R<sub>e</sub>)CONR<sub>a</sub>R<sub>b</sub> or (CH<sub>2</sub>)<sub>n</sub>NR<sub>c</sub>R<sub>d</sub>,

n is 0 or 1,

R<sub>a</sub> and R<sub>b</sub>, independently, are hydrogen, (C<sub>1-7</sub>)alkyl, (C<sub>1-4</sub>)alkoxy(C<sub>1-4</sub>)alkyl, benzyl, phenyl, (C<sub>3-5</sub>)cycloalkyl(C<sub>1-4</sub>)alkyl, pyridyl, pyridyl(C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkyl piperidinyl,

tetrahydropyranyl, (C<sub>7-8</sub>)bicycloalkyl, 1-aza-(C<sub>7-9</sub>)bicycloalkyl; (C<sub>5-6</sub>)cycloalkyl substituted by hydroxy; or pyrazolyl or isoxazolyl being unsubstituted or substituted by (C<sub>1-4</sub>)alkyl;


R<sub>c</sub> and R<sub>d</sub>, independently, are hydrogen, tetrahydronaphthyl, (C<sub>1-4</sub>)alkoxy tetrahydronaphthyl, (C<sub>3-5</sub>)cycloalkyl being unsubstituted or substituted by halophenyl; chromanyl being substituted by halogen, (C<sub>1-4</sub>)alkyl or (C<sub>3-7</sub>)cycloalkyl; or (C<sub>1-4</sub>)alkyl being unsubstituted or mono or disubstituted by (C<sub>5-7</sub>)cycloalkyl, phenyl, (C<sub>1-4</sub>)alkoxy phenyl, di(C<sub>1-4</sub>)alkoxy phenyl, halophenyl, phenoxy phenyl, (C<sub>1-4</sub>)alkyl phenyl, hydroxy (C<sub>1-4</sub>)alkyl phenyl, (C<sub>1-4</sub>)alkoxy (C<sub>1-4</sub>)alkoxy phenyl, naphthyl, pyridyl, thiadiazolyl, benzimidazolyl or furyl; R<sub>e</sub> is (C<sub>1-8</sub>)alkyl, and

R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub> and R<sub>9</sub>, independently, are hydrogen or halogen, in free base or acid addition salt form.

Claim 4. (Original) A process for the preparation of a compound of formula I as defined in claim 1, or a salt thereof, which includes the steps of acylating a compound of formula II



wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are as defined in claim 1, with an acid of formula III



wherein X, Y, A, B, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub> and R<sub>9</sub> are as defined in claim 1, or an activated form thereof, and recovering the so obtained compound of formula I in free base or acid addition salt form.

Claim 5. (Canceled)

Claim 6. (Canceled)

Claim 7. (Previously presented) A pharmaceutical composition comprising a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, in association with a pharmaceutical carrier or diluent.

Claim 8-11. (Canceled)